Prostaglandin E1 infusion for small vessel arterial ischaemia

Area of Science:

• Vascular Medicine
• Pharmacology
• Regenerative Medicine

Background:

• Severe arterial ischemia, characterized by rest pain, digital ulceration, and gangrene, often results from small vessel disease.
• Limited treatment options exist for improving digital perfusion in these patients.

Purpose of the Study:

• To evaluate the efficacy of Prostaglandin E1 (PGE1) infusions in improving digital perfusion in patients with severe arterial ischemia.
• To assess the safety and duration of therapeutic effects of PGE1.

Main Methods:

• A study involving 49 patients with severe arterial ischemia received Prostaglandin E1 (PGE1) infusions at varying doses (6, 10, or 14 ng/kg/min).
• Clinical effects were quantified using Doppler studies, pulse volume recordings, and infrared radiometry.
• Patient-reported outcomes included pain assessment and ulcer healing.

Main Results:

• PGE1 infusions significantly increased pulse volume amplitude (P < 0.001) and digital temperatures (P < 0.001), with sustained improvements at 6 weeks.
• The majority of patients reported pain improvement.
• Two-thirds of superficial ulcers healed within 6 weeks post-infusion.

Conclusions:

• Prostaglandin E1 (PGE1) is a safe and effective vasodilator for improving digital perfusion in severe arterial ischemia.
• PGE1 treatment offers sustained clinical benefits, including pain relief and ulcer healing, for several weeks.